InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,496.00
(
0.09%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.16
(
-0.34%
)
Bitcoin
60,471.73
(
-2.51%
)
Post# of 120
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Just-Keep-Trying

Send PM Follow Ignore
Followers 0
Posts 1474
Boards Moderated 0
Alias Born 02/10/2022

Just-Keep-Trying

Re: TheFinalCD post# 6

Sunday, 03/06/2022 11:05:17 AM

Sunday, March 06, 2022 11:05:17 AM

Post# of 120
Likely very wrong, S-M.:

“Among participants with evaluable baseline tumor biopsies, tumor burden reduction was achieved exclusively in those with high ATRC-101 target expression.”

"Pantginis concluded, reiterating the Buy rating and the $25 per share target on the stock."

https://seekingalpha.com/news/3809653-atreca-spikes-as-hc-wainwright-welcomes-updated-cancer-drug-data

https://pulse2.com/atreca-bcel-stock-why-the-price-is-much-higher-today/

https://www.marketbeat.com/instant-alerts/nasdaq-bcel-options-data-report-2022-03/
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up